Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) Stock Competitors & Peer Comparison
See AMPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMPH | $28.83 | +1.18% | 1.3B | 10.03 | $2.93 | N/A |
| TAK | $20.81 | -1.33% | 66B | 15.03 | $1.39 | +3.38% |
| TEVA | $42.99 | +0.05% | 49.4B | 14.47 | $2.93 | N/A |
| HLN | $9.13 | +1.75% | 39.8B | 18.53 | $0.49 | +2.19% |
| ZTS | $82.13 | -0.24% | 34.1B | 12.53 | $6.58 | +2.56% |
| VTRS | $21.01 | +2.54% | 23.9B | 8.27 | $2.52 | +2.31% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $26.56 | -1.06% | 13.4B | 25.26 | $1.06 | N/A |
| RDY | $14.76 | -1.93% | 12.4B | 31.63 | $0.47 | +0.56% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
AMPH vs TAK Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TAK has a market cap of 66B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TAK trades at $20.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TAK's P/E ratio is 15.03. In terms of profitability, AMPH's ROE is +0.13%, compared to TAK's ROE of +0.05%. Regarding short-term risk, AMPH is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
AMPH vs TEVA Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TEVA has a market cap of 49.4B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TEVA trades at $42.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TEVA's P/E ratio is 14.47. In terms of profitability, AMPH's ROE is +0.13%, compared to TEVA's ROE of +0.06%. Regarding short-term risk, AMPH is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TEVA's competition here
Haleon plc (NYSE: HLN)
AMPH vs HLN Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, HLN has a market cap of 39.8B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while HLN trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas HLN's P/E ratio is 18.53. In terms of profitability, AMPH's ROE is +0.13%, compared to HLN's ROE of +0.10%. Regarding short-term risk, AMPH is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
AMPH vs ZTS Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ZTS has a market cap of 34.1B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ZTS trades at $82.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ZTS's P/E ratio is 12.53. In terms of profitability, AMPH's ROE is +0.13%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, AMPH is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
AMPH vs VTRS Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, VTRS has a market cap of 23.9B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while VTRS trades at $21.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas VTRS's P/E ratio is 8.27. In terms of profitability, AMPH's ROE is +0.13%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, AMPH is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
AMPH vs ITCI Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AMPH's ROE is +0.13%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, AMPH is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
AMPH vs ELAN Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ELAN has a market cap of 13.4B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ELAN trades at $26.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ELAN's P/E ratio is 25.26. In terms of profitability, AMPH's ROE is +0.13%, compared to ELAN's ROE of -0.02%. Regarding short-term risk, AMPH is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
AMPH vs RDY Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, RDY has a market cap of 12.4B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while RDY trades at $14.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas RDY's P/E ratio is 31.63. In terms of profitability, AMPH's ROE is +0.13%, compared to RDY's ROE of +0.07%. Regarding short-term risk, AMPH is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check RDY's competition here
Catalent, Inc. (NYSE: CTLT)
AMPH vs CTLT Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AMPH's ROE is +0.13%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, AMPH is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CTLT's competition here
Alkermes plc (NASDAQ: ALKS)
AMPH vs ALKS Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ALKS trades at $47.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ALKS's P/E ratio is 48.59. In terms of profitability, AMPH's ROE is +0.13%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, AMPH is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
AMPH vs AMRX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, AMRX has a market cap of 7.4B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while AMRX trades at $21.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas AMRX's P/E ratio is 23.64. In terms of profitability, AMPH's ROE is +0.13%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, AMPH is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
AMPH vs LNTH Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while LNTH trades at $101.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas LNTH's P/E ratio is 17.08. In terms of profitability, AMPH's ROE is +0.13%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, AMPH is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
AMPH vs INDV Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while INDV trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas INDV's P/E ratio is 9.94. In terms of profitability, AMPH's ROE is +0.13%, compared to INDV's ROE of -3.53%. Regarding short-term risk, AMPH is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check INDV's competition here
Bausch Health Companies Inc. (NYSE: BHC)
AMPH vs BHC Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while BHC trades at $8.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas BHC's P/E ratio is 2.11. In terms of profitability, AMPH's ROE is +0.13%, compared to BHC's ROE of +0.59%. Regarding short-term risk, AMPH is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check BHC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
AMPH vs HCM Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while HCM trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas HCM's P/E ratio is 148.74. In terms of profitability, AMPH's ROE is +0.13%, compared to HCM's ROE of +0.01%. Regarding short-term risk, AMPH is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check HCM's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
AMPH vs RGC Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, RGC has a market cap of 2.6B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while RGC trades at $5.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas RGC's P/E ratio is -523.00. In terms of profitability, AMPH's ROE is +0.13%, compared to RGC's ROE of -1.61%. Regarding short-term risk, AMPH is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check RGC's competition here
Perrigo Company plc (NYSE: PRGO)
AMPH vs PRGO Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while PRGO trades at $16.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas PRGO's P/E ratio is 6.73. In terms of profitability, AMPH's ROE is +0.13%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, AMPH is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
AMPH vs DCPH Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AMPH's ROE is +0.13%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, AMPH is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DCPH's competition here
Alvotech (NASDAQ: ALVOW)
AMPH vs ALVOW Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ALVOW has a market cap of 2.1B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ALVOW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ALVOW's P/E ratio is 33.51. In terms of profitability, AMPH's ROE is +0.13%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, AMPH is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ALVOW's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
AMPH vs AVDL Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, AMPH's ROE is +0.13%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, AMPH is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check AVDL's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
AMPH vs ETON Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ETON has a market cap of 1.9B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ETON trades at $68.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ETON's P/E ratio is 177.74. In terms of profitability, AMPH's ROE is +0.13%, compared to ETON's ROE of +1.05%. Regarding short-term risk, AMPH is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ETON's competition here
Embecta Corp. (NASDAQ: EMBCV)
AMPH vs EMBCV Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AMPH's ROE is +0.13%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, AMPH is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check EMBCV's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
AMPH vs TRLV Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TRLV trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TRLV's P/E ratio is -4.50. In terms of profitability, AMPH's ROE is +0.13%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, AMPH is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TRLV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
AMPH vs DVAX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas DVAX's P/E ratio is -41.89. In terms of profitability, AMPH's ROE is +0.13%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, AMPH is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DVAX's competition here
Supernus, Inc. (NASDAQ: SUPN)
AMPH vs SUPN Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, SUPN has a market cap of 1.7B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while SUPN trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas SUPN's P/E ratio is -37.97. In terms of profitability, AMPH's ROE is +0.13%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, AMPH is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SUPN's competition here
Alvotech (NASDAQ: ALVO)
AMPH vs ALVO Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ALVO trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ALVO's P/E ratio is -7.93. In terms of profitability, AMPH's ROE is +0.13%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, AMPH is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ALVO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
AMPH vs TARO Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TARO's P/E ratio is 30.05. In terms of profitability, AMPH's ROE is +0.13%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AMPH is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check TARO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
AMPH vs ANIP Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ANIP trades at $70.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ANIP's P/E ratio is 8.25. In terms of profitability, AMPH's ROE is +0.13%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, AMPH is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ANIP's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
AMPH vs PCRX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while PCRX trades at $36.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas PCRX's P/E ratio is 14.03. In terms of profitability, AMPH's ROE is +0.13%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, AMPH is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PCRX's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
AMPH vs PAHC Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while PAHC trades at $35.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas PAHC's P/E ratio is 11.82. In terms of profitability, AMPH's ROE is +0.13%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, AMPH is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
AMPH vs CRON Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while CRON trades at $3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas CRON's P/E ratio is 17.46. In terms of profitability, AMPH's ROE is +0.13%, compared to CRON's ROE of +0.05%. Regarding short-term risk, AMPH is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CRON's competition here
Harrow Health, Inc. (NASDAQ: HROW)
AMPH vs HROW Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while HROW trades at $28.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas HROW's P/E ratio is -30.67. In terms of profitability, AMPH's ROE is +0.13%, compared to HROW's ROE of -0.91%. Regarding short-term risk, AMPH is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
AMPH vs PETQ Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AMPH's ROE is +0.13%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, AMPH is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
AMPH vs COLL Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, COLL has a market cap of 796.6M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while COLL trades at $24.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas COLL's P/E ratio is 3.07. In terms of profitability, AMPH's ROE is +0.13%, compared to COLL's ROE of +0.12%. Regarding short-term risk, AMPH is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
AMPH vs IRWD Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, IRWD has a market cap of 794.8M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while IRWD trades at $4.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas IRWD's P/E ratio is 6.17. In terms of profitability, AMPH's ROE is +0.13%, compared to IRWD's ROE of -0.81%. Regarding short-term risk, AMPH is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
AMPH vs EVO Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, EVO has a market cap of 600.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while EVO trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas EVO's P/E ratio is -2.39. In terms of profitability, AMPH's ROE is +0.13%, compared to EVO's ROE of -0.26%. Regarding short-term risk, AMPH is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
AMPH vs BDSI Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AMPH's ROE is +0.13%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AMPH is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check BDSI's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
AMPH vs TKNO Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TKNO has a market cap of 538.7M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TKNO trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TKNO's P/E ratio is -28.16. In terms of profitability, AMPH's ROE is +0.13%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, AMPH is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TKNO's competition here
Kamada Ltd. (NASDAQ: KMDA)
AMPH vs KMDA Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, KMDA has a market cap of 467.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while KMDA trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas KMDA's P/E ratio is 21.32. In terms of profitability, AMPH's ROE is +0.13%, compared to KMDA's ROE of +0.09%. Regarding short-term risk, AMPH is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check KMDA's competition here
Evolus, Inc. (NASDAQ: EOLS)
AMPH vs EOLS Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, EOLS has a market cap of 450.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while EOLS trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas EOLS's P/E ratio is -21.57. In terms of profitability, AMPH's ROE is +0.13%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, AMPH is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
AMPH vs AQST Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, AQST has a market cap of 441.8M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while AQST trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas AQST's P/E ratio is -5.42. In terms of profitability, AMPH's ROE is +0.13%, compared to AQST's ROE of +2.55%. Regarding short-term risk, AMPH is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AQST's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
AMPH vs ACB Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ACB has a market cap of 339.6M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ACB trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ACB's P/E ratio is -3.73. In terms of profitability, AMPH's ROE is +0.13%, compared to ACB's ROE of -0.15%. Regarding short-term risk, AMPH is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ACB's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
AMPH vs EBS Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, EBS has a market cap of 309.7M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while EBS trades at $6.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas EBS's P/E ratio is 4.19. In terms of profitability, AMPH's ROE is +0.13%, compared to EBS's ROE of -0.61%. Regarding short-term risk, AMPH is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
AMPH vs ALIM Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AMPH's ROE is +0.13%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, AMPH is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ALIM's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
AMPH vs TLRY Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TLRY has a market cap of 296.4M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TLRY trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TLRY's P/E ratio is -1.89. In terms of profitability, AMPH's ROE is +0.13%, compared to TLRY's ROE of -0.10%. Regarding short-term risk, AMPH is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TLRY's competition here
Landec Corporation (NASDAQ: LNDC)
AMPH vs LNDC Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AMPH's ROE is +0.13%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, AMPH is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check LNDC's competition here
Canopy Growth Corporation (NASDAQ: CGC)
AMPH vs CGC Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, CGC has a market cap of 250.8M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while CGC trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas CGC's P/E ratio is -1.33. In terms of profitability, AMPH's ROE is +0.13%, compared to CGC's ROE of -0.37%. Regarding short-term risk, AMPH is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CGC's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
AMPH vs LFCR Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, LFCR has a market cap of 241.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while LFCR trades at $6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas LFCR's P/E ratio is -5.02. In terms of profitability, AMPH's ROE is +0.13%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, AMPH is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
AMPH vs TYHT Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AMPH's ROE is +0.13%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, AMPH is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
AMPH vs SIGA Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, SIGA has a market cap of 224.9M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while SIGA trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas SIGA's P/E ratio is 11.59. In terms of profitability, AMPH's ROE is +0.13%, compared to SIGA's ROE of -0.20%. Regarding short-term risk, AMPH is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
AMPH vs REPH Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas REPH's P/E ratio is -8.04. In terms of profitability, AMPH's ROE is +0.13%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AMPH is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check REPH's competition here
Glass House Brands Inc (NYSE: GLAS)
AMPH vs GLAS Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, GLAS has a market cap of 172M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while GLAS trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas GLAS's P/E ratio is -3.49. In terms of profitability, AMPH's ROE is +0.13%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, AMPH is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check GLAS's competition here
Theratechnologies Inc. (NASDAQ: THTX)
AMPH vs THTX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas THTX's P/E ratio is -28.83. In terms of profitability, AMPH's ROE is +0.13%, compared to THTX's ROE of +0.36%. Regarding short-term risk, AMPH is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
AMPH vs ASRT Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ASRT's P/E ratio is -7.10. In terms of profitability, AMPH's ROE is +0.13%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, AMPH is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
AMPH vs DERM Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, DERM has a market cap of 124.8M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while DERM trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas DERM's P/E ratio is -20.09. In terms of profitability, AMPH's ROE is +0.13%, compared to DERM's ROE of -0.20%. Regarding short-term risk, AMPH is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check DERM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
AMPH vs ORGO Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ORGO has a market cap of 124.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ORGO trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ORGO's P/E ratio is 31.96. In terms of profitability, AMPH's ROE is +0.13%, compared to ORGO's ROE of -0.47%. Regarding short-term risk, AMPH is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ORGO's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
AMPH vs CRDL Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, CRDL has a market cap of 123.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while CRDL trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas CRDL's P/E ratio is -4.06. In terms of profitability, AMPH's ROE is +0.13%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, AMPH is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
AMPH vs OGI Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, OGI has a market cap of 120.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while OGI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas OGI's P/E ratio is 1.91. In terms of profitability, AMPH's ROE is +0.13%, compared to OGI's ROE of +0.21%. Regarding short-term risk, AMPH is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check OGI's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
AMPH vs SCTL Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AMPH's ROE is +0.13%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AMPH is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
AMPH vs BGM Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, BGM has a market cap of 109.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while BGM trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas BGM's P/E ratio is -1.79. In terms of profitability, AMPH's ROE is +0.13%, compared to BGM's ROE of -0.05%. Regarding short-term risk, AMPH is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
AMPH vs PROC Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas PROC's P/E ratio is 1.53. In terms of profitability, AMPH's ROE is +0.13%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AMPH is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
AMPH vs OPTN Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AMPH's ROE is +0.13%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, AMPH is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
AMPH vs ZOM Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AMPH's ROE is +0.13%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, AMPH is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
AMPH vs GRVI Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AMPH's ROE is +0.13%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, AMPH is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check GRVI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
AMPH vs CPIX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, CPIX has a market cap of 79.4M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while CPIX trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas CPIX's P/E ratio is -13.25. In terms of profitability, AMPH's ROE is +0.13%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, AMPH is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CPIX's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
AMPH vs ZYBT Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ZYBT has a market cap of 71.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ZYBT's P/E ratio is -7.50. In terms of profitability, AMPH's ROE is +0.13%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, AMPH is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
AMPH vs ZYNE Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AMPH's ROE is +0.13%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AMPH is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
AMPH vs SSIC Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AMPH's ROE is +0.13%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, AMPH is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
AMPH vs VLNS Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AMPH's ROE is +0.13%, compared to VLNS's ROE of N/A. Regarding short-term risk, AMPH is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
AMPH vs DRRX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas DRRX's P/E ratio is -4.44. In terms of profitability, AMPH's ROE is +0.13%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, AMPH is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
AMPH vs TLPH Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TLPH has a market cap of 54.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TLPH trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TLPH's P/E ratio is -3.89. In terms of profitability, AMPH's ROE is +0.13%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, AMPH is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TLPH's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
AMPH vs JUPW Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AMPH's ROE is +0.13%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, AMPH is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check JUPW's competition here
InterCure Ltd. (NASDAQ: INCR)
AMPH vs INCR Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, INCR has a market cap of 43.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while INCR trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas INCR's P/E ratio is -3.83. In terms of profitability, AMPH's ROE is +0.13%, compared to INCR's ROE of -0.09%. Regarding short-term risk, AMPH is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check INCR's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
AMPH vs QLI Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas QLI's P/E ratio is -4.92. In terms of profitability, AMPH's ROE is +0.13%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AMPH is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
AMPH vs HEXO Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AMPH's ROE is +0.13%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AMPH is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
AMPH vs RMTI Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, RMTI has a market cap of 29.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while RMTI trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas RMTI's P/E ratio is -5.46. In terms of profitability, AMPH's ROE is +0.13%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, AMPH is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check RMTI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
AMPH vs SHPH Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, SHPH has a market cap of 25.4M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while SHPH trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas SHPH's P/E ratio is -0.25. In terms of profitability, AMPH's ROE is +0.13%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, AMPH is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SHPH's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
AMPH vs CPHI Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, CPHI has a market cap of 24.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while CPHI trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas CPHI's P/E ratio is -1.31. In terms of profitability, AMPH's ROE is +0.13%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, AMPH is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CPHI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
AMPH vs CYTH Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AMPH's ROE is +0.13%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, AMPH is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check CYTH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
AMPH vs TXMD Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, TXMD has a market cap of 20.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while TXMD trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas TXMD's P/E ratio is 88.64. In terms of profitability, AMPH's ROE is +0.13%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, AMPH is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
AMPH vs AYTU Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, AYTU has a market cap of 19.7M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while AYTU trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas AYTU's P/E ratio is -1.53. In terms of profitability, AMPH's ROE is +0.13%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, AMPH is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
AMPH vs EVOK Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas EVOK's P/E ratio is -7.97. In terms of profitability, AMPH's ROE is +0.13%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, AMPH is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
AMPH vs ACRX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AMPH's ROE is +0.13%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, AMPH is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ACRX's competition here
Optimi Health Corp. (NASDAQ: OPTH)
AMPH vs OPTH Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, OPTH has a market cap of 12.9M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while OPTH trades at $2.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas OPTH's P/E ratio is -1.45. In terms of profitability, AMPH's ROE is +0.13%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, AMPH is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check OPTH's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
AMPH vs AGRX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas AGRX's P/E ratio is -0.89. In terms of profitability, AMPH's ROE is +0.13%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, AMPH is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check AGRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
AMPH vs CABR Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, CABR has a market cap of 8.6M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while CABR trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas CABR's P/E ratio is -1.21. In terms of profitability, AMPH's ROE is +0.13%, compared to CABR's ROE of -3.86%. Regarding short-term risk, AMPH is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check CABR's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
AMPH vs INM Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, INM has a market cap of 8.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while INM trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas INM's P/E ratio is -5.07. In terms of profitability, AMPH's ROE is +0.13%, compared to INM's ROE of -3.04%. Regarding short-term risk, AMPH is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check INM's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
AMPH vs NLTX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AMPH's ROE is +0.13%, compared to NLTX's ROE of -0.44%. Regarding short-term risk, AMPH is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
AMPH vs LCI Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas LCI's P/E ratio is -0.04. In terms of profitability, AMPH's ROE is +0.13%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AMPH is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
AMPH vs ADMP Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ADMP's P/E ratio is -0.08. In terms of profitability, AMPH's ROE is +0.13%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, AMPH is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check ADMP's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
AMPH vs SBFM Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, SBFM has a market cap of 6.1M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while SBFM trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas SBFM's P/E ratio is -0.47. In terms of profitability, AMPH's ROE is +0.13%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, AMPH is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SBFM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
AMPH vs SNOA Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, SNOA has a market cap of 5.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while SNOA trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas SNOA's P/E ratio is -1.03. In terms of profitability, AMPH's ROE is +0.13%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, AMPH is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
AMPH vs MNK Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas MNK's P/E ratio is -0.44. In terms of profitability, AMPH's ROE is +0.13%, compared to MNK's ROE of -0.33%. Regarding short-term risk, AMPH is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check MNK's competition here
cbdMD, Inc. (AMEX: YCBD)
AMPH vs YCBD Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, YCBD has a market cap of 4.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while YCBD trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas YCBD's P/E ratio is -0.95. In terms of profitability, AMPH's ROE is +0.13%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, AMPH is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check YCBD's competition here
Flora Growth Corp. (NASDAQ: FLGC)
AMPH vs FLGC Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas FLGC's P/E ratio is -0.19. In terms of profitability, AMPH's ROE is +0.13%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, AMPH is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check FLGC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
AMPH vs SBFMW Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, SBFMW has a market cap of 4.2M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while SBFMW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas SBFMW's P/E ratio is N/A. In terms of profitability, AMPH's ROE is +0.13%, compared to SBFMW's ROE of -0.24%. Regarding short-term risk, AMPH is more volatile compared to SBFMW. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check SBFMW's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
AMPH vs GELS Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while GELS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas GELS's P/E ratio is -0.95. In terms of profitability, AMPH's ROE is +0.13%, compared to GELS's ROE of -0.36%. Regarding short-term risk, AMPH is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check GELS's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
AMPH vs PLXP Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas PLXP's P/E ratio is -0.22. In terms of profitability, AMPH's ROE is +0.13%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, AMPH is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for AMPH.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
AMPH vs ATNX Comparison November 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMPH stands at 1.3B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, AMPH is priced at $28.83 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMPH currently has a P/E ratio of 10.03, whereas ATNX's P/E ratio is -0.02. In terms of profitability, AMPH's ROE is +0.13%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, AMPH is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for AMPH.Check ATNX's competition here